LNP-RNA Therapeutics 2-Day Virtual Symposium Agenda

*All Times Listed in Eastern Daylight Time*

**All Information is Subject to Change**

Wednesday - April 6, 2022

8:50 AM - 9:00 AM - Welcome & Logistics
Juliana Haggerty, EngD Head of Centre of Excellence - Lipid Nanoparticle CPI
Dominik Witzigmann, PhD Chief Executive Officer NanoVation Therapeutics
9:00 AM - 9:30 AM - LNP-RNA History
The tangled history of mRNA-LNP vaccines Elie Dolgin, PhD Journalist Freelance
9:30 AM - 10:45 AM - Session 1: RNA Therapeutics - Setting the Scene
Tailored LNP solutions for mRNA-based cancer immunotherapy Stefaan De Koker VP discovery eTheRNA immunotherapies
Industrial perspective: translating mRNA LNPs from discovery to development Marianna Yanez Arteta, PhD Associate Director AstraZeneca
Industrial perspective: translating mRNA LNPs from discovery to development Alan Sabirsh, PhD Principal Scientist AstraZeneca
BREAK: 10:45 AM - 11:10 AM
11:10 AM - 12:25 PM - Session 2: Improved in vitro/in vivo Methods for Developing RNA Therapeutics
Lipid Nanoparticles for Extrahepatic Delivery of mRNA Gaurav Sahay, PhD Associate Professor Oregon State University
Improved in vitro methods for safety assessment in development of RNA Therapeutics Geir Klinkenberg, Dr. Research Manager SINTEF Industry
Delivering RNA to New Tissues by Testing Thousands of Nanoparticles in vivo James Dahlman, PhD Associate Professor Georgia Institute of Technology
BREAK: 12:25 PM - 1:10 PM
1:10 PM - 2:50 PM - Session 3: Genome Editing
Targeting metabolic liver diseases by in vivo base- and prime editing Gerald Schwank, PhD Prof Universität Zürich
Multiplexed screening of LNPs in vivo enabled by nucleic acid barcoding Cory Sago, PhD Senior Director, Head of LNP Discovery Beam Therapeutics
Writing DNA with RNA Cecilia Cotta-Ramusino, PhD SVP Tessera
Prime editing Sabine Fuchs, PhD, MD, Pharmacist Pediatrician and PI (Principal Investigator/Group Leader) in Metabolic Diseases Associate Professor UMC-Utrecht
BREAK: 2:50 PM - 3:10 PM
3:10 PM - 4:00 PM - Session 4
Treatment of Rare Genetic Diseases using Gene Therapy Aneal Khan, MSC, MD, FRCPC, FCCMG Pediatrician and Medical Geneticist M.A.G.I.C. Clinic Ltd. in Calgary and Vancouver (Metabolics and Genetics in Canada)
Innovative therapies for Hemophilia: Way beyond substitution therapy David Lillicrap, MD Professor Queen's University
4:00 PM - 5:00 PM - Panel Discussion on Unmet Clinical Needs/Rare Diseases
Panel Participant Barbara D Insley, LL.B, CFA Chair and Executive Director Rare Trait Hope Society
5:00 PM - Closing Day 1

Thursday - April 7, 2022

8:50 AM - Welcome and Logistics
Juliana Haggerty, EngD Head of Centre of Excellence - Lipid Nanoparticle CPI
Dominik Witzigmann, PhD Chief Executive Officer NanoVation Therapeutics
9:00 AM - 10:15 AM - Session 5: Future in RNA Design
Development of a 2nd generation SARs-CoV2 vaccine utilizing self-amplifying RNA and viral targets beyond Spike Karin Jooss, PhD Executive Vice President and Head of Research & Development Gritstone bio
Leveraging the design of self-replicating RNA to enhance RNA therapeutics Andrew Geall, PhD Chief Development Officer Replicate Bioscience
Programming mRNA for Cancer Immunotherapy Tasuku Kitada, Ph.D. Co-founder, Board Director, President, and Head of R&D Strand Therapeutics
BREAK: 10:15 AM - 10:35 AM
10:35 AM - 11:50 AM - Session 6: Delivery Platform Technologies
Simultaneous quantification of multiple RNA cargoes co-loaded into nanoparticle-based delivery systems Camilla Foged, PhD Professor University of Copenhagen
On the Structural Features of Lipid Nanoparticle Formulations of Nucleic Acids Jayesh Kulkarni, PhD Chief Scientific Officer NanoVation Therapeutics
Next Generation lipids for RNA Delivery Dan Peer, PhD Professor and Director, Laboratory of Precision Nanomedicine NeoVac & Tel Aviv University
BREAK: 11:50 AM - 12:35 PM
12:35 PM - 2:15 PM - Session 7: Manufacturing / New Technologies
Development of a Platform for LNP-RNA Manufacture - Challenges and Opportunities Philip Probert, PhD Head of Technical CPI
Digital Innovations in the Bio Pharma Industry Adrian Abbotts, BSc Biotechnology Business Development Manager Cell & Gene Therapies Siemens Digital Industries
Next generation DNA templates for the production of mRNA Amy Walker, PhD Director of Discovery 4basebio
Optimal Self-Assembly of Lipid Nanoparticles (LNP) in a Ring Micromixer Mostafa Nakach, PhD Section head of formulation & process development within Biologic drug product development & manufacturing Sanofi
BREAK: 2:15 PM - 2:35 PM
2:35PM - 3:25 PM - Session 8: Cell therapies ex vivo/in vivo incl. Car-T
mRNA Lipid Nanoparticle Reprogramming of Immune Cell for the Treatment of Heart Disease Haig Aghajanian, PhD Adjunct Assistant Professor of Medicine University of Pennsylvania
Ionizable Lipid Nanoparticles Induce potent Tfh responses and can serve as protein adjuvants Mohamad-Gabriel Alameh, PhD Director Engineered mRNA and Targeted Nanomedicine Core at UPenn University of Pennsylvania
3:25 PM - 4:25 PM - Panel Discussion: Future of LNP-RNA Systems
Panel Discussion Lead Sanya Puri, PhD Director AstraZeneca
Panel Discussion: Next-Gen LNPs for Tissue/Cell-Specific Delivery Priya Karmali, PhD Chief Technology Officer Capstan Therapeutics
Panel Discussion Ruchi Shah, PhD Associate Director Eli Lilly & Company
4:25 PM - Closing Day 2